These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 574221)

  • 21. Treatment of "on-off effect" with a dopa decarboxylase inhibitor.
    Sweet RD; McDowell FH; Wasterlain CG; Stern PH
    Arch Neurol; 1975 Aug; 32(8):560-3. PubMed ID: 1156214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of a slow release preparation of levodopa on Parkinson's disease in combination with a peripheral decarboxylase inhibitor.
    Saarinen A; Myllylä VV; Tokola O; Hokkanen E
    Acta Neurol Scand; 1978 Dec; 58(6):340-9. PubMed ID: 369277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Niacin depletion in Parkinsonian patients treated with L-dopa, benserazide and carbidopa.
    Bender DA; Earl CJ; Lees AJ
    Clin Sci (Lond); 1979 Jan; 56(1):89-93. PubMed ID: 477187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Six-year results of treatment with levodopa plus benzerazide in Parkinson's disease.
    Barbeau A; Roy M
    Neurology; 1976 May; 26(5):399-404. PubMed ID: 944392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's disease in the elderly: a long-term efficacy study of levodopa/benserazide combination therapy.
    Mondal BK; Mondal KN
    Pharmatherapeutica; 1986; 4(9):571-6. PubMed ID: 3094036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levodopa/benserazide ('Madopar') combination therapy in elderly patients with parkinsonism.
    Williams BO; Carlyle D
    Curr Med Res Opin; 1979; 6(1):1-7. PubMed ID: 378553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
    Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
    [No Abstract]   [Full Text] [Related]  

  • 29. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
    Savery F
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
    [No Abstract]   [Full Text] [Related]  

  • 30. [The clinical experience with the decarboxylase-blocked levodopa (Nacom) in the Parkinsonism patients].
    Völler GW; Deze J
    ZFA (Stuttgart); 1976 Mar; 52(7):380-8. PubMed ID: 773025
    [No Abstract]   [Full Text] [Related]  

  • 31. [Carbiodopa-levodopa therapy (Sinemet) in the treatment of parkinsonian patients. Results of 4 years of treatment].
    Martínez-Lage JM; Burguera JA; Deldago G; Zubieta JL
    Arch Neurobiol (Madr); 1978; 41(1):3-18. PubMed ID: 697513
    [No Abstract]   [Full Text] [Related]  

  • 32. Allergy to Carbidopa.
    Cansino-Torres MA; Sandoval-Rodríguez V; Sáenz-Farret M; Zúñiga-Ramírez C
    Clin Neuropharmacol; 2018; 41(2):75-79. PubMed ID: 29432287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition.
    Sachs C; Berglund B; Kaijser L
    Acta Neurol Scand; 1985 Jan; 71(1):37-42. PubMed ID: 3976351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
    Cedarbaum JM; Breck L; Kutt H; McDowell FH
    Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effectiveness of two extracerebral DOPA decarboxylase inhibitors in Parkinson disease.
    Lieberman A; Estey E; Gopinathan G; Ohashi T; Sauter A; Goldstein M
    Neurology; 1978 Sep; 28(9 Pt 1):964-8. PubMed ID: 567768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
    Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
    J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative clinical investigation of the therapeutic effect of levodopa alone and in combination with a decarboxylase inhibitor (carbidopa) in cases of Parkinson's disease.
    Wajsbort J; Dorner A; Wajsbort E
    Curr Med Res Opin; 1978; 5(9):695-708. PubMed ID: 367714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combined treatment of Parkinsonism with L-dopa and peripheral dopa decarboxylase inhibitors--clinical course of 13 cases and levels of serum/dopa and dopamine].
    Mizuno Y; Yoshida M; Obayashi T; Ueki A
    Rinsho Shinkeigaku; 1976 Jul; 16(7):511-9. PubMed ID: 986921
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term treatment of Parkinson's disease with L-Dopa and Dopa-decarboxylase inhibitor: therapeutic results and side effects.
    Battistin L; Meneghetti G; Rigotti S; Saia A
    Acta Neurol Scand; 1978 Feb; 57(2):186-92. PubMed ID: 347868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.